304 results about "Hedgehog" patented technology

The present invention relates to an adult mammal which exhibits growth or replication of abnormal cells in a target tissue or organ by over-expressing Hedgehog protein in such target tissue or organ. The present invention also relates to a method of preparing an adult animal model of prostate cancer. The invention further relates to a method of evaluating an agent for treating prostate cancer.

The present invention relates to prevention of congenital deformations The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events gene expression during prenatal development, post-natal development and during development in the adult organism.

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.

The present invention relates to therapeutic combinations and methods of inhibiting the proliferation of cancerous cells, the abnormal growth of cells, and tumor cell growth using the combination of a hedgehog inhibitor with chemotherapy and / or radiation therapy. The present invention also relates to methods of enhancing the antiproliferative effect of chemotherapy and / or radiation therapy in a mammalian cancer patient undergoing either chemotherapy or radiation or a combination of radiation and chemotherapy by co-administering a therapeutically amount of a hedgehog inhibitor, concurrently or sequentially, with the chemotherapy and / or radiation therapy.

Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in digestive tract cancers, including esophagus, stomach, biliary tract, and pancreatic cancer, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a digestive tract cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a digestive tract tumor to treatment with an Hh pathway antagonist.

Compounds, compositions, kits and methods for modulating hedgehog pathway activity, and treating conditions related to abnormal or aberrant hedgehog pathway activity, are disclosed.

The present application is directed to the discovery that hedgehog proteins, and agents which effect the activities thereof, can be used to control the formation and / or maintenance of cartilage and bone.

The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.

The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators. The synergistic effects of oxysterols and bone morphogenic proteins are also disclosed.

Hedgehog agonists and antagonists can be used to regulate angiogenesis, and to prevent angiogenesis driven pathologies. Furthermore, hedgehog agonists and antagonists have utility in modulating tissue repair and in the treatment of many forms of cancer.

The invention relates to an external drug for eliminating cancer tumor bumps and alleviating pains thereof, which belongs to the field of medicine and overcomes the disadvantages that the prior anodyne for terminal cancer has drug addiction and gradually reduced pains alleviating effect. The external drug consists of asafetida, dried lacquer, poison nut, blood clam shell, pangolin, hirudo, gadfly, soil insect, rhizoma corydalis, frankincense, myrrh, rhizoma sparganii, zedoary, rhizoma ligustici wallichii, notoginseng, dragon's blood, hedgehog skin, peach kernel, safflower, radix aconiti, radix aconiti feri, scorpion, centipede, snake skin, oldenlandia diffusa, glabrous greenbrier rhizome, ginseng, radix astragali, american ginseng, angelica, radix salviae miltiorrhizae, muskiness and the like. The external drug has the advantages that the drug can eliminae or obviously alleviate pains of complication of the terminal cancer, has stable analgesic effect, and has no side effects compared with the prior anodyne used for the same disease symptom.

The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and Gli signaling pathway, including agents that inhibit GLI synthesis and / or function. The present invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of prostate cancer. Methods of treating cancer, including prostate cancer are also provided using small organic compounds, siRNAs and blocking antibodies that inhibit or block the SHH / GLI pathway.

The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.

The invention relates to a method of treating cancer. The method includes administering systemically a therapeutically effective amount of a small molecule hedgehog pathway inhibitor, such that the concentration of the inhibitor in the blood does not vary by more than about ±30% from the average concentration, and such that the concentration remains at or below the maximum tolerated dose of the inhibitor for a time period of at least about one day.

A method for preparing golden mushroom, pleurotu ostreatus, hedgehog fungus, mushroom, glossy ganoderma, black fungus with part of or all of extrinsic intrusion weeds such as Canada goldenrod, false Chinese sorghum, annual awning, small erigeron, wild pond wormwood and plane weed; and method preparing mushroom and glossy ganoderma with eupa, while in current method, raw material are usually as follows: cotton-seed hull, chip, straw, ryegrass, maize-ear, bran and rice bran. The proportion of weeds consumption in total cultural material is 20-80%. The invention can control extrinsic intrusion weeds, bring in economic benefit, and release raw material shortage, and the low cost is good for factory production and ecological balance maintenance.

The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

The invention discloses a type of quinoline derivatives. The quinoline derivatives are used as inhibitors for hedgehog channels, and in particular, used as SMO inhibitors. The compounds disclosed by the invention can be used for treating hedgehog channel-related diseases comprising cancers.

The invention discloses a star-like radial allocation method for artificial reefs, which is characterized in that a cubic reef form with the side length of 1 to 2 meters is used as a main reef, 3 to 8 auxiliary reefs with the height of 80 to 120 centimeters are uniformly distributed on the circumference which uses the main reef as the central point, the main reef and each auxiliary reef are connected through a stone connection bridge with the length of 3 to 6 meters, and the categories of the adjacent auxiliary reefs are diverse. The artificial reefs are closer to the reality and are favorable for the balance of the ecological system, and the stone connection bridge serving as a radiation belt provides a bridge for the movement of rare seafood among the reefs and plays a role in sheltering. Through on-site sea area tests, the rare seafood such as sea cucumber, sea hedgehog, abalone and the like can rest in gaps among the main reef, the auxiliary reefs and the stone connection bridges or on the surfaces; the good growth condition of algae on the reefs provides baits for the rare seafood, so the proliferation effect of the rare seafood is obvious; and reef-associated fishes such as hexagrammos otakii, sebastes schlegeli and the like rest in the main reef and the auxiliary reefs, so the whole reef group structure is stable and forms a good small ecosystem.

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

Anti-hedgehog antibodies directed at blocking the binding of hedgehog to its receptor patched-1, will impair lipid metabolism and storage. This invention presents methods for the treatment of a variety of lipid metabolism and lipid storage disorders, aberrant apolipoprotein expression, atherosclerosis and other lipid associated disorders using lipid modulators such as hedgehog antagonists or hedgehog agonists.

The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. Certain aspects of the invention are directed to preparations of hedgehog polypeptides, agonists, antagonists, or other molecules which regulate patched or smoothened signalling, and their uses as immunomodulatory agents.

The invention discloses a hedgehog SiO2 hollow microsphere and preparation method thereof. Block polymer is taken as soft template; block polymer solution is added into organic solvent / water two-phase system, so as to form stable emulsion, co-guiding agent and silicon source are dissolved in organic solvent and mixed to be uniform, and the emulsion is added; under the conditions of faintly acid and alkalescence, silicon precursor is hydrolyzed and condensed; then drying and calcination subsequent treatment are carried out; and finally the hedgedog SiO2 hollow microsphere is obtained. The invention is easy to implement and is economic and practicable, the grain diameter distribution of the prepared hedgedog SiO2 hollow microsphere is uniform, and the cavity diameter and spinous density are adjustable.

Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w / w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w / w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

The invention discloses a hedgehog-resembling damping shell applicable to air-dropping miniature robots. The hedgehog-resembling damping shell comprises a hedgehog-resembling outer rubber layer, a duralumin layer, a support pillar buffer layer, a buffer spring, an electromagnetic lock, a fixed iron sheet, hard rubber seats, a control circuit board and the like. The damping shell can be loaded with a miniature robotic explorer, and plays a role in resisting to landing overload and buffering protection; when in an air-dropping process, an acceleration sensor on a shell circuit board monitors acceleration in real time, and when the acceleration reaches a set threshold, a delay program is started; when in a landing process, the damping shell adsorbs ground impact by a multi-stage buffering mode to protect an internally carried object; after landing for a certain time t, the control circuit cuts off the power supply of the electromagnetic lock, the damping shell is divided into four parts, the shell and the hard rubber seats are popped out by a plurality of compressed fixing springs, and then the miniature robot can drive out to perform explosion and reconnaissance movements.

The invention discloses a compound preparation for treating mouth mucosa lichen planus. The compound preparation is prepared from the following raw materials in part by weight: 16 to 28 parts of common lophatherum herb, 16 to 28 parts of largetrifoliolious bugbane rhizome, 16 to 28 parts of toad coat, 16 to 28 parts of golden thread, 16 to 28 parts of multiflora rose root, 16 to 28 parts of caudate sweetleaf, 12 to 25 parts of villous amomum fruit, 12 to 25 parts of trogopterus dung, 12 to 25 parts of costustoot, 12 to 25 parts of Christina loosestrife herb, 12 to 25 parts of hedgehog fungus, 12 to 25 parts of blister beetle, 6 to 18 parts of notoginseng root, 6 to 18 parts of lotus stamen, 6 to 18 parts of eggplant root, 6 to 18 parts of edible bayberry bark, 6 to 18 parts of calculus bovis factitius, 6 to 18 parts of vitamin C, 1 to 12 parts of axillary choerospondias fruit, 1 to 12 parts of saffron, 1 to 12 parts of ginseng flower, 1 to 12 parts of gleditsia seed, 1 to 12 parts of loquat leaf and 1 to 12 parts of water chestnut. According to the compound preparation, the raw materials are compatible with each other to condition viscera, so the compound preparation has the effects of removing necrotic tissue, promoting tissue regeneration and repairing deformed mucosae quickly.

The present invention provides methods and compositions for promoting the formation of three dimensional cartilage matrices. The present invention further provides methods of treating diseases and injuries involving cartilage and bone using the three dimensional cartilage matrices provided herein.